Levy RH - Search Results

1

Inhibition-based metabolic drug-drug interactions: predictions from in vitro data.

Yao C, Levy RH. Yao C, et al. Among authors: levy rh. J Pharm Sci. 2002 Sep;91(9):1923-35. doi: 10.1002/jps.10179. J Pharm Sci. 2002. PMID: 12210040 Review.

2

Seizure detection and neuromodulation: A summary of data presented at the XIII conference on new antiepileptic drug and devices (EILAT XIII).

Bialer M, Johannessen SI, Levy RH, Perucca E, Tomson T, White HS, Koepp MJ. Bialer M, et al. Among authors: levy rh. Epilepsy Res. 2017 Feb;130:27-36. doi: 10.1016/j.eplepsyres.2017.01.004. Epub 2017 Jan 16. Epilepsy Res. 2017. PMID: 28113141

3

Progress report on new antiepileptic drugs: a summary of the Ninth Eilat Conference (EILAT IX).

Bialer M, Johannessen SI, Levy RH, Perucca E, Tomson T, White HS. Bialer M, et al. Among authors: levy rh. Epilepsy Res. 2009 Jan;83(1):1-43. doi: 10.1016/j.eplepsyres.2008.09.005. Epub 2008 Nov 12. Epilepsy Res. 2009. PMID: 19008076

4

A comparative study of the effect of carbamazepine and valproic acid on the pharmacokinetics and metabolic profile of topiramate at steady state in patients with epilepsy.

Mimrod D, Specchio LM, Britzi M, Perucca E, Specchio N, La Neve A, Soback S, Levy RH, Gatti G, Doose DR, Maryanoff BE, Bialer M. Mimrod D, et al. Among authors: levy rh. Epilepsia. 2005 Jul;46(7):1046-54. doi: 10.1111/j.1528-1167.2005.06805.x. Epilepsia. 2005. PMID: 16026556

5

Risk of Clinically Relevant Pharmacokinetic-Based Drug-Drug Interactions with Drugs Approved by the U.S. Food and Drug Administration Between 2013 and 2016.

Yu J, Zhou Z, Tay-Sontheimer J, Levy RH, Ragueneau-Majlessi I. Yu J, et al. Among authors: levy rh. Drug Metab Dispos. 2018 Jun;46(6):835-845. doi: 10.1124/dmd.117.078691. Epub 2018 Mar 23. Drug Metab Dispos. 2018. PMID: 29572333

6

Intestinal Drug Interactions Mediated by OATPs: A Systematic Review of Preclinical and Clinical Findings.

Yu J, Zhou Z, Tay-Sontheimer J, Levy RH, Ragueneau-Majlessi I. Yu J, et al. Among authors: levy rh. J Pharm Sci. 2017 Sep;106(9):2312-2325. doi: 10.1016/j.xphs.2017.04.004. Epub 2017 Apr 13. J Pharm Sci. 2017. PMID: 28414144 Review.

7

A useful tool for drug interaction evaluation: the University of Washington Metabolism and Transport Drug Interaction Database.

Hachad H, Ragueneau-Majlessi I, Levy RH. Hachad H, et al. Among authors: levy rh. Hum Genomics. 2010 Oct;5(1):61-72. doi: 10.1186/1479-7364-5-1-61. Hum Genomics. 2010. PMID: 21106490 Free PMC article.

8

Quantitative correlations among CYP3A sensitive substrates and inhibitors: literature analysis.

Ragueneau-Majlessi I, Boulenc X, Rauch C, Hachad H, Levy RH. Ragueneau-Majlessi I, et al. Among authors: levy rh. Curr Drug Metab. 2007 Dec;8(8):810-4. doi: 10.2174/138920007782798135. Curr Drug Metab. 2007. PMID: 18220561

9

Qualitative analysis of the role of metabolites in inhibitory drug-drug interactions: literature evaluation based on the metabolism and transport drug interaction database.

Isoherranen N, Hachad H, Yeung CK, Levy RH. Isoherranen N, et al. Among authors: levy rh. Chem Res Toxicol. 2009 Feb;22(2):294-8. doi: 10.1021/tx800491e. Chem Res Toxicol. 2009. PMID: 19216580 Free PMC article. Review.

10

Past, Present, and Future of Drug-Drug Interactions.

Levy RH, Ragueneau-Majlessi I. Levy RH, et al. Clin Pharmacol Ther. 2019 Jun;105(6):1286-1288. doi: 10.1002/cpt.1349. Epub 2019 Feb 17. Clin Pharmacol Ther. 2019. PMID: 30773619 Review. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results